With acquisition of functionality in FRβ restricted to the tumor microenvironment, we decided to evaluate whether a folate-targeted TLR7 agonist might be able to induce a proinflammatory phenotype in tumor myeloid cells without activating immune cells in healthy tissues. Here, FOLR2 is linked to neoplasm.